REBECCA YANG, PHARMD
Pharmacy at Sunset Blvd, Los Angeles, CA

7883707, Feb 8, 2011

Mar 27, 2009

12/412986

Emil D. Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

A61K 39/385

4241931, 4241981

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

7485314, Feb 3, 2009

May 6, 2002

10/141668

Emil D. Kakkis - Novato CA, US
Merry Passage - Torrance CA, US
Thomas Lester - Harbor City CA, US
Rebecca Yang - Los Angeles CA, US
Christopher Tanaka - Gardena CA, US

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance CA

A61K 45/00

4242781, 424 941

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

2004000, Jan 15, 2004

May 5, 2003

10/429314

Emil Kakkis - Novato CA, US
Thomas Lester - Harbor City CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

A61K038/13, A61K039/00

514/011000, 424/185100

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

2005019, Sep 1, 2005

Nov 3, 2004

10/980648

Emil Kakkis - Novato CA, US
Thomas Lester - Cardiff CA, US
Merry Passage - Torrance CA, US
Christopher Tanaka - Gardena CA, US
Rebecca Yang - Los Angeles CA, US

A61K039/00, A61K038/13, A61K031/7024, A61K031/522

424184100, 514011000, 514263310, 514023000

Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.